Establishing 3 national pharmaceutical factories in Sharjah with investments of 308.7 million dirhams

The International Pharmacy and Medicine Conference in its 13th edition (ICPM 2025) revealed the establishment of 3 new pharmaceutical factories in the Emirate of Sharjah, in partnership between national and international companies, with an investment value exceeding 84 million dollars, equivalent to 308.7 million dirhams.

The signing ceremony was held yesterday evening, Thursday, on the sidelines of the activities of the third and last day of (ICPM 2025), at the Sharjah Research, Technology and Innovation Complex, to join these three pharmaceutical factories to the current pharmaceutical factory in Sharjah, to represent a strong and new pharmaceutical boost in the UAE in the UAE as General and Sharjah in particular.

After the signing ceremony of the agreements, the three factories will specialize in the production of respiratory products, eye drops, antibiotic capsules and stomach medicines, in addition to first aid materials and products, as construction or design operations began in these factories, and will be completed in mid -2026 or its end.

Dr. Munir Ryan, Chairman of the Organizing Committee of the International Conference on Pharmacy and Medicine (ICPM 2025), stressed that these agreements support the strategic partnership in the drug sector between international companies with Emirati drugs and factories, which establishes the role of the UAE drug economy at the level of the countries of the region, stressing the importance of focusing on Industry in the field of medicine to be a fundamental tributary of the state on the economic side.

He said that this batch of new pharmaceutical factories is a strong indicator of drug production in the UAE and entering the system of creativity and drug innovation, which supports the state in the field of global competitiveness in the health sector and drug economies in the country, indicating that the first factory is to make 8 types of eye drops and 4 products related to the device Psychological, which is the product of a partnership between a national company and another Indian.

He said that the cost of establishing this factory is about 44 million dollars and the construction is completed in late 2026, to be operated and produced, which is made up of 3 floors for research and analysis, laboratories, production lines and warehouses, adding that this factory will depend on the use of artificial intelligence and modern technologies globally in Drug production and manufacturing field.

He stated that the second factory will be on an area of ​​10,000 feet, with an investment value of about 35 million dollars and consisting of 3 roles to produce antibiotic capsules, stomach medicines, gelatin capsules and secondary packing lines.

He stated that this factory started work in the construction stages and that is completed in the middle of next year, and the factory is scheduled to produce 600 million capsules annually upon reaching the full operational capacity, and this will be reached on more than one operating stage.

And that the third factory will be for medical equipment and is held on an area of ​​20 thousand feet and specializes in first aid products, and work begins at the end of this year, and focuses on mobilizing and packaging first aid products, and aims to export these products abroad.

He explained that the construction and operation operations are expected to be completed early next year, and its investment cost reaches 5 million dollars.

He stressed that the UAE has become an open laboratory for the latest innovations and smart solutions in the pharmaceutical and pharmaceutical industry, which enhances the leadership and competitiveness of the state in the health and pharmaceutical field and also as a center for advanced technologies and smart applications and the use of artificial intelligence, noting that the steady increase and accelerated growth in the number of pharmaceutical factories in the UAE, They represent a strong indication of the growth of its position in the field of pharmaceutical industries, and the government’s keenness to support investment in the drug sector, with infrastructure, airports and free zones.